IT Services - Germany



Buy (old: Buy) 06.03.2025

EUR 1.30 (old: EUR 1.10)

FY24p beats profitability expectations; chg. est. & PT

Topic: QBY released FY24 preliminary figures, where top-line was in line with expectations but **EBITDA** significantly ahead of the company's guidance and especially our estimates. In detail:

FY24 sales came in at € 193m, which is in line with our and street's estimates (both € 193m). Sales were once more driven by the Managed Services segment (+4.9% yoy to € 135m) while the Consulting segment showed a 5.7% yoy decline to € 57.3m.

Strong gross margin improvement by 3.4pp yoy to 18.0% driven mostly by an improved near- and off-shore ratio of 14% at YE. Thanks to the discontinuation of low margin consulting projects as well as a further expanding near- and off-shore ratio, gross margin is seen to further improve to over 20% in FY25e.

EBITDA beat. FY24 EBITDA came in at € 10.5m, thus significantly beating our estimate of € 9.2m, consensus (€ 9.2m) as well as the company's guidance (€ 8-10m). Besides the improved gross profit, efficiency measures in SG&A were the main drivers behind the stronger than expected improvement (+83% yoy even including last years positive one-off).

The strong release was topped off by a strongly improved FCF of € 3.2m (company definition). Mind you, that QBY defines FCF as the total change in net liquidity (excl. M&A). According to our calculation, FY24 FCF should have come in at € 5.7m.

In addition to the release of the preliminary figures, management also put out an FY25 guidance, targeting sales in the range of \in 184-190m, an EBITDA of \in 12-15m as well as sustained positive net income. While the EBITDA outlook is in line with our old estimates (\in 14.6m), our sales figure was significantly above with \in 204m. The gap is mainly explained by an accounting change. In accordance with IFRS 15, a total of \in 12.6m FY24 sales, mainly related to SAP and Microsoft contracts, will no longer be accounted as revenues, as only the profits from the respective customers relationships will be accounted. Hence, the new guidance has to be put into perspective with a base revenue of \in 180m, implying 2.2-5.6% growth.

-continued-

Y/E 31.12 (EUR m)	2021	2022	2023	2024e	2025e	2026e
Sales	155.2	173.0	189.3	192.6	189.9	200.5
Sales growth	8.2%	11.5%	9.4%	1.8%	-1.4%	5.6%
EBITDA	31.7	5.4	5.7	10.5	14.7	17.9
Net debt (if net cash=0)	-54.3	-30.7	-30.4	-36.1	-47.5	-60.3
FCF	-14.9	-4.7	3.9	5.7	11.4	12.8
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
EPS pro forma	0.08	-0.27	-0.14	-0.04	0.01	0.04
EBITDA margin	20.5%	3.1%	3.0%	5.5%	7.7%	8.9%
ROCE	9.1%	-23.2%	-7.8%	-4.1%	2.0%	5.5%
EV/sales	0.3	0.4	0.3	0.3	0.2	0.2
EV/EBITDA	1.3	11.9	11.1	5.5	3.2	1.9
PER	9.5	-2.8	-5.3	-18.3	74.3	20.6
Adjusted FCF yield	60.0%	-2.1%	-9.0%	10.1%	20.4%	34.0%

Source: Company data, NuWays, Close price as of 05.03.2025



Market data					
Share price (in €)	0.73				
Market cap (in € m)	92.2				
Number of shares (in m pcs)	124.6				
Enterprise value (in € m)	46.8				
Ø trading volume (6 months)	81,317				


	Identifier
Bloomberg	QBY GR
Reuters	QSCGF
WKN	513700
ISIN	DE0005137004


Key shareholders	
Gerd Eickers	12.7%
Dr. Bernd Schlobohm	12.7%
Free Float	74.7%


Estimates changes					
	<u>2024e</u>	<u>2025e</u>	<u>2026e</u>		
Sales	-0%	-7%	-7%		
EBIT	-27%	10%	7%		
EPS	-6%	16%	8%		

Comment on changes

 Changes reflect the release of the FY24 preliminary figures.







Company description

q.beyond AG is a German-based digital solutions company, active in the fields of cloud management, system applications and products, IoT, and other IT services. The company operates in several countries with a strong focus on the DACH-region.

Guidance

- FY25 Sales: € 184-190m
- FY25 EBITDA: € 12-15m
- FY25: Positive net income

Preview / Review - 06.03.2025



€ 30m M&A war chest. During yesterday's CC, CEO Rixen confirmed that the company is at an advanced stage to acquire 1-2 targets in FY25. Here, the management is looking for margin accretive targets with € >10m sales. Given the recent announcement of the (likely) new government intending to spend big on defense and infrastructure going forward, the company will likely look for targets with a high public sector exposure (healthcare, energy, defense), which was also confirmed during the CC. Rixen also explained that the company could spend up to € 30m on M&A given the company's strong net cash position. Mind you, that future M&A is not reflected in our model, thus providing upside to our estimates.

Given the strong release as well as the promising outlook, valuation remains attractive at 3.2x EV/ EBITDA FY25e (1.9x FY26e)

We reiterate **BUY with a new € 1.30 PT** (old: € 1.10) based on DCF.

Preview / Review - 06.03.2025



Financials

Profit and loss (EUR m)	2021	2022	2023	2024e	2025e	2026e
Sales	155.2	173.0	189.3	192.6	189.9	200.5
Sales growth	8.2%	11.5%	9.4%	1.8%	-1.4%	5.6%
Cost of sales	124.9	145.6	161.7	158.0	151.5	157.8
Gross profit	30.3	27.5	27.6	34.6	38.4	42.8
Sales and marketing	12.6	12.6	14.6	11.5	11.8	12.2
General and administration	17.2	14.9	16.4	14.0	13.3	14.0
Research and development	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	36.3	6.0	9.4	1.4	1.5	1.6
Other operating expenses	5.1	0.5	0.3	0.1	0.2	0.2
Total operating expenses	0.0	0.0	0.0	0.0	0.0	0.0
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	31.7	5.4	5.7	10.5	14.7	17.9
Depreciation	13.0	12.5	11.0	10.6	7.9	7.3
Amortisation of goodwill	0.0	15.8	0.0	0.0	0.0	0.0
Amortisation of intangible assets	3.6	9.4	5.7	4.9	4.5	4.0
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	15.2	-32.3	-10.9	-5.0	2.3	6.6
Interest income	0.0	0.1	0.7	0.8	0.9	1.1
Interest expenses	0.3	0.2	0.5	0.4	0.4	0.4
Investment income	-0.3	-0.9	-0.5	-0.3	0.0	0.0
Financial result	-0.5	-1.0	-0.3	0.1	0.5	0.7
Recurring pretax income from continuing operations	14.6	-33.2	-11.3	-4.9	2.8	7.3
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	14.6	-33.2	-11.3	-4.9	2.8	7.3
Income tax expense	4.8	-0.2	5.2	-0.9	0.6	1.8
Net income from continuing operations	9.8	-33.1	-16.4	-4.0	2.3	5.5
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0
Net income	9.8	-33.1	-16.4	-4.0	2.3	5.5
Minority interest	0.1	0.2	1.0	1.0	1.0	1.0
Net profit (reported)	9.7	-33.3	-17.5	-5.0	1.2	4.5
Average number of shares	124.5	124.6	124.6	124.6	124.6	124.6
EPS reported	0.08	-0.27	-0.14	-0.04	0.01	0.04
	2021	2022	2023	2024e	2025e	2026e
Profit and loss (common size)	2021 100.0%	2022	2023 100 0%	2024e	2025e	
Profit and loss (common size) Sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Profit and loss (common size) Sales Cost of sales	100.0% 80.5%	100.0% 84.1%	100.0% 85.4%	100.0% 82.0%	100.0% 79.8%	100.0% 78.7%
Profit and loss (common size) Sales Cost of sales Gross profit	100.0% 80.5% 19.5%	100.0% 84.1% 15.9%	100.0% 85.4% 14.6%	100.0% 82.0% 18.0%	100.0% 79.8% 20.2%	100.0% 78.7% 21.3%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing	100.0% 80.5% 19.5% 8.1%	100.0% 84.1% 15.9% 7.3%	100.0% 85.4% 14.6% 7.7%	100.0% 82.0% 18.0% 6.0%	100.0% 79.8% 20.2% 6.2%	100.0% 78.7% 21.3% 6.1%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration	100.0% 80.5% 19.5% 8.1% 11.1%	100.0% 84.1% 15.9% 7.3% 8.6%	100.0% 85.4% 14.6% 7.7% 8.6%	100.0% 82.0% 18.0% 6.0% 7.3%	100.0% 79.8% 20.2% 6.2% 7.0%	100.0% 78.7% 21.3% 6.1% 7.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development	100.0% 80.5% 19.5% 8.1% 11.1% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0%	100.0% 78.7% 21.3% 6.1% 7.0% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8%	100.0% 78.7% 21.3% 6.1% 7.0% 0.0% 0.8%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1%	100.0% 78.7% 21.3% 6.1% 7.0% 0.0% 0.8% 0.1%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0%	100.0% 78.7% 21.3% 6.1% 7.0% 0.0% 0.8% 0.1%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 0.0%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 0.0%	100.0% 78.7% 21.3% 6.1% 7.0% 0.0% 0.8% 0.1% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 0.0% 5.5%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7%	100.0% 78.7% 21.3% 6.1% 7.0% 0.0% 0.8% 0.1% 0.0% 8.9%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Unusual or infrequent items EBITDA Depreciation	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 0.0% 3.1% 7.2%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 0.0% 5.5%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1%	100.0% 78.7% 21.3% 6.1% 7.0% 0.0% 0.8% 0.1% 0.0% 8.9% 3.6%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 0.0% 3.1% 7.2% 9.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 0.0% 5.5% 0.0%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1% 0.0%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 8.9% 3.6% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Fotal operating expenses Junusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4% 0.0% 2.3%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 0.0% 5.5% 5.5% 0.0% 2.6%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1% 0.0% 2.4%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 3.6% 0.0% 2.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1% 0.0% 2.4% 0.0%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 3.6% 0.0% 2.0% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net)	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1% 0.0% 2.4%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 8.9% 3.6% 0.0% 2.0% 0.0% 3.3%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Jusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets mpairment charges EBIT (inc revaluation net) nterest income	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 0.0% 3.0% 0.0% 3.0% 0.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.4%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 8.9% 3.6% 0.0% 2.0% 0.0% 3.3% 0.5%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Jnusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets mpairment charges EBIT (inc revaluation net) nterest income nterest expenses	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.4% 0.2%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 8.9% 3.6% 0.0% 2.0% 0.0% 3.3% 0.5% 0.2%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% -5.8% 0.4% 0.3% -0.3%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.4% 0.2% -0.1%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2% 0.0%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 8.9% 3.6% 0.0% 2.0% 0.0% 3.3% 0.2% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Jusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets mpairment charges EBIT (inc revaluation net) nterest income nterest expenses nvestment income Financial result	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg.	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% -0.5% neg.	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% 3.0% 0.0% 3.0% 0.0% 3.0% 0.0% 3.0% 0.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.2% -0.1% 0.1%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2% 0.0% 0.3%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 3.6% 0.0% 2.0% 0.0% 3.3% 0.2% 0.2% 0.0% 0.4%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Junusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets mpairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% -0.5% neg19.2%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% -5.8% 0.3% -0.3% neg5.9%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.4% 0.2% -0.1% 0.1% -2.5%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2% 0.0% 0.3% 1.5%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 3.6% 0.0% 3.6% 0.0% 3.7%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% 0.1% -0.5% neg19.2% 0.0%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% -5.8% 0.3% -0.3% neg5.9% 0.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.2% -0.1% 0.1% -2.5% 0.0%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2% 0.0% 0.3% 1.5% 0.0%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 3.6% 0.0% 2.0% 0.0% 3.3% 0.5% 0.2% 0.4% 3.7% 0.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% -0.5% neg19.2%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% -5.8% 0.3% -0.3% neg5.9% 0.0% -5.9%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.1% 0.1% -2.5% 0.0% -2.5%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2% 0.0% 0.3% 1.5% 0.0% 1.5%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 3.6% 0.0% 2.0% 0.0% 3.3% 0.2% 0.2% 0.4% 3.7% 0.0% 3.7%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% -0.5% neg19.2% 0.0% -19.2% 0.5%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% -5.8% 0.3% -0.3% neg5.9% 0.0% -46.0%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.1% -2.5% 0.0% -2.5% 17.7%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2% 0.0% 1.5% 0.0% 1.5% 20.0%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 3.6% 0.0% 2.0% 0.0% 3.3% 0.5% 0.2% 0.0% 0.4% 3.7% 0.0% 3.7% 25.0%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% -0.5% neg19.2% 0.0% -19.2% 0.5% -19.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% -5.8% 0.4% 0.3% -0.3% neg5.9% 0.0% -46.0% -8.7%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.1% 0.1% -2.5% 0.0% -2.5% 17.7% -2.1%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2% 0.0% 1.5% 0.0% 1.5% 20.0% 1.5%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 3.6% 0.0% 2.0% 0.0% 3.3% 0.5% 0.2% 0.0% 0.4% 3.7% 0.0% 25.0% 2.7%
Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3% 6.3%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% -0.5% neg19.2% 0.0% -19.2% 0.5% -19.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% -5.8% 0.4% 0.3% -0.3% neg5.9% 0.0% -46.0% -8.7%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.1% 0.1% -2.5% 0.0% -2.5% 17.7% -2.1%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2% 0.0% 1.5% 0.0% 1.5% 20.0% 1.5% 20.0% 1.2%	21.3% 6.1% 7.0% 0.0% 0.8% 0.1% 0.0% 3.6% 0.0% 2.0% 0.0% 3.3% 0.5% 0.2% 0.0% 3.7% 0.0% 2.50% 2.7% 2.7%
Profit and loss (common size) Sales Cost of sales Gross profit	100.0% 80.5% 19.5% 8.1% 11.1% 0.0% 23.4% 3.3% 0.0% 20.5% 8.4% 0.0% 2.3% 0.0% 9.8% 0.0% 0.2% -0.2% neg. 9.4% 0.0% 9.4% 32.7% 6.3%	100.0% 84.1% 15.9% 7.3% 8.6% 0.0% 3.5% 0.3% 0.0% 3.1% 7.2% 9.1% 5.4% 0.0% -18.7% 0.1% -0.5% neg19.2% 0.0% -19.2% 0.5% -19.1%	100.0% 85.4% 14.6% 7.7% 8.6% 0.0% 5.0% 0.1% 0.0% 3.0% 5.8% 0.0% 3.0% 0.0% -5.8% 0.4% 0.3% -0.3% neg5.9% 0.0% -46.0% -8.7%	100.0% 82.0% 18.0% 6.0% 7.3% 0.0% 0.7% 0.0% 5.5% 5.5% 0.0% 2.6% 0.0% -2.6% 0.1% 0.1% -2.5% 0.0% -2.5% 17.7% -2.1%	100.0% 79.8% 20.2% 6.2% 7.0% 0.0% 0.8% 0.1% 0.0% 7.7% 4.1% 0.0% 2.4% 0.0% 1.2% 0.5% 0.2% 0.0% 1.5% 0.0% 1.5% 20.0% 1.5%	100.0% 78.7% 21.3% 6.1% 7.0% 0.8% 0.1% 0.0% 3.6% 0.0% 2.0% 0.0% 3.3% 0.5% 0.2% 0.0% 3.7% 0.0% 25.0% 2.7%

Source: Company data, NuWays

Preview / Review - 06.03.2025



Balance sheet (EUR m)	2021	2022	2023	2024e	2025e	2026e
Intangible assets	51.9	28.7	28.1	24.1	20.6	17.6
Property, plant and equipment	39.0	37.8	31.8	26.2	20.7	16.0
Financial assets	6.3	5.3	2.8	2.8	2.8	2.8
FIXED ASSETS	97.2	71.8	62.6	53.1	44.1	36.4
Inventories	0.2	0.2	0.1	0.2	0.2	0.3
Accounts receivable	35.4	39.7	34.1	36.9	36.4	38.5
Other assets and short-term financial assets	5.0	4.9	11.8	11.8	11.8	11.8
Liquid assets	56.7	36.4	37.6	43.3	54.7	67.5
Deferred taxes	0.0	0.0	0.0	0.0	0.0	0.0
Deferred charges and prepaid expenses CURRENT ASSETS	5.8 103.1	8.2	8.0 91.7	8.0	8.0 111.2	8.0 126.1
TOTAL ASSETS	200.3	89.3 161.1	154.3	100.3 153.5	155.3	162.4
TOTAL ASSETS	200.3	101.1	154.5	155.5	155.5	102.4
SHAREHOLDERS EQUITY	147.1	115.1	97.8	94.6	96.9	102.9
MINORITY INTEREST	0.3	0.5	1.5	1.5	1.5	1.0
Long-term liabilities to banks	0.0	0.0	0.0	0.0	0.0	0.0
Bonds (long-term)	0.0	0.0	0.0	0.0	0.0	0.0
other interest-bearing liabilities	2.4	5.7	7.2	7.2	7.2	7.2
Provisions for pensions and similar obligations	4.8	2.3	2.1	2.1	2.1	2.1
Other provisions and accrued liabilities	4.7	2.4	5.0	5.0	5.0	5.0
NON-CURRENT LIABILITIES	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Short-term liabilities to banks	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	25.4	24.6	25.9	29.0	28.6	30.2
Advance payments received on orders	0.0 0.0	0.0 2.2	0.0	0.0	0.0 6.0	0.0 6.0
Accrued taxes Other liabilities (incl. from loose and rental contracts)			6.0	6.0 6.6		
Other liabilities (incl. from lease and rental contracts) Deferred taxes	13.7 1.6	7.7 0.0	6.6 0.8	0.8	6.6 0.8	6.6 0.8
Deferred income	0.4	0.0	1.3	0.6	0.6	0.6
CURRENT LIABILITIES	39.0	32.4	32.5	35.6	35.2	36.8
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	200.3	161.1	154.3	153.5	155.3	162.4
Balance sheet (common size)	2021	2022	2023	2024e	2025e	2026e
Intangible assets	25.9%	17.8%	18.2%	15.7%	13.3%	10.9%
Property, plant and equipment	19.5%	23.5%	20.6%	17.1%	13.4%	9.8%
Financial assets	3.1%	3.3%	1.8%	1.8%	1.8%	1.7%
FIXED ASSETS	48.5%	44.6%	40.6%	34.6%	28.4%	22.4%
Inventories	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%
Accounts receivable	17.7%	24.6%	22.1%	24.1%	23.4%	23.7%
Other assets and short-term financial assets	2.5%	3.0%	7.7%	7.7%	7.6%	7.3%
Liquid assets	28.3%	22.6%	24.4%	28.2%	35.2%	41.6%
Deferred taxes	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred charges and prepaid expenses	2.9%	5.1%	5.2%	5.2%	5.1%	4.9%
CURRENT ASSETS	51.5%	55.4%	59.4%	65.4%	71.6%	77.6%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
SHAREHOLDERS EQUITY	73.4%	71.5%	63.4%	61.6%	62.4%	63.3%
MINORITY INTEREST	0.1%	0.3%	1.0%	1.0%	1.0%	0.6%
Long-term liabilities to banks	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Bonds (long-term)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
other interest-bearing liabilities	1.2%	3.5%	4.7%	4.7%	4.7%	4.5%
Provisions for pensions and similar obligations	2.4%	1.4%	1.4%	1.4%	1.4%	1.3%
Other provisions and accrued liabilities	2.3%	1.5%	3.2%	3.2%	3.2%	3.1%
NON-CURRENT LIABILITIES	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Short-term liabilities to banks	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts payable	12.7%	15.3%	16.8%	18.9%	18.4%	18.6%
Advance payments received on orders	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	0.0%	1.3%	3.9%	3.9%	3.9%	3.7%
Accrued taxes			4.00/	4.20/	4.00/	4.1%
Accrued taxes Other liabilities (incl. from lease and rental contracts)	6.8%	4.8%	4.3%	4.3%	4.2%	7.170
Other liabilities (incl. from lease and rental contracts) Deferred taxes	6.8% 0.8%	0.0%	0.5%	0.5%	0.5%	0.5%
Other liabilities (incl. from lease and rental contracts) Deferred taxes Deferred income	6.8% 0.8% 0.2%	0.0% 0.3%	0.5% 0.9%	0.5% 0.4%	0.5% 0.4%	0.5% 0.3%
Other liabilities (incl. from lease and rental contracts) Deferred taxes	6.8% 0.8%	0.0%	0.5%	0.5%	0.5%	0.5% 0.3% 22.7% 100.0%

Source: Company data, NuWays

Preview / Review - 06.03.2025



Cash flow statement (EUR m)	2021	2022	2023	2024e	2025e	2026e
Net profit/loss	9.8	-33.1	-16.4	-4.0	2.3	5.5
Depreciation of fixed assets (incl. leases)	12.7	17.9	11.0	8.3	7.9	7.3
Amortisation of goodwill & intangible assets Other costs affecting income / expanses	3.6 -33.2	20.0 -4.3	5.7 2.7	4.9 0.0	4.5 0.0	4.0 0.0
Other costs affecting income / expenses Cash flow from operating activities	-33.2 -12.6	-4.3 -7.8	1.5	4.7	11.0	12.9
Increase/decrease in inventory	0.0	0.0	0.1	-0.1	0.0	-0.0
Increase/decrease in accounts receivable	2.4	-4.1	5.5	-2.8	0.5	-2.0
Increase/decrease in accounts payable	0.5	6.2	1.3	3.1	-0.4	1.6
Increase/decrease in other working capital positions	-3.5	-3.9	-3.4	0.0	0.0	0.0
Increase/decrease in working capital	-0.6	-1.7	3.6	0.2	0.1	-0.5
Cash flow from operating activities	-7.7	-1.3	6.5	9.4	14.7	16.3
CAPEX	7.3	3.5	2.6	3.7	3.4	3.5
Payments for acquisitions	15.5	10.6	0.0	0.0	0.0	0.0
Financial investments	6.4	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	53.8	0.1	0.9	0.0	0.0	0.0
Cash flow from investing activities	24.7	-14.0	-1.7	-3.7	-3.4	-3.5
Cash flow before financing	17.0	-15.2	4.8	5.7	11.4	12.8
Increase/decrease in debt position	-5.4	-0.0	-0.5	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.2	0.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	0.0	-5.1	-3.0	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities	-5.3	-5.1	-3.5	0.0	0.0	0.0
Increase/decrease in liquid assets	11.8	-20.3	1.3	5.7	11.4	12.8
Liquid assets at end of period	56.7	36.4	37.6	43.3	54.7	67.5
Key ratios (EUR m)	2021	2022	2023	2024e	2025e	2026e
P&L growth analysis						
Sales growth	8.2%	11.5%	9.4%	1.8%	-1.4%	5.6%
EBITDA growth	-1704.4%	-83.1%	7.1%	82.8%	39.9%	21.7%
EBIT growth	-180.6%	-312.6%	-66.1%	-54.3%	-146.9%	181.9%
EPS growth	-148.7%	-442.8%	-47.5%	-71.1%	-124.6%	260.1%
Efficiency						
Sales per employee	152.5	153.8	170.3	173.2	168.2	172.5
EBITDA per employee	31.2	4.8	5.2	9.4	13.0	15.4
No. employees (average)	1,018	1,125	1,112	1,112	1,129	1,163
Balance sheet analysis		0 =0/		0.40/		
Avg. working capital / sales	4.2%	8.7%	4.9%	6.1%	4.3%	4.2%
Inventory turnover (sales/inventory)	623.1	797.3	1,736.5	800.0	800.0	800.0
Accounts receivable turnover Accounts payable turnover	83.3 74.2	83.7 61.8	65.8 58.5	70.0 55.0	70.0 55.0	70.0 55.0
Cash flow analysis	14.2	01.0	30.3	55.0	55.0	55.0
Free cash flow	-14.9	-4.7	3.9	5.7	11.4	12.8
Free cash flow/sales	-9.6%	-2.7%	2.1%	3.0%	6.0%	6.4%
FCF / net profit	neg.	14.3%	neg.	neg.	498.8%	233.0%
Capex / sales	8.8%	2.0%	1.4%	1.9%	1.8%	1.7%
Solvency						
Net debt	-54.3	-30.7	-30.4	-36.1	-47.5	-60.3
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	13.0%	6.8%	10.6%	5.6%	5.0%	5.0%
Returns						
ROCE	9.1%	-23.2%	-7.8%	-4.1%	2.0%	5.5%
ROE	6.6%	-28.9%	-17.9%	-5.3%	1.3%	4.3%
Adjusted FCF yield	60.0%	-2.1%	-9.0%	10.1%	20.4%	34.0%
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
DPS	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	0.08	-0.27	-0.14	-0.04	0.01	0.04
Average number of shares	124.5	124.6	124.6	124.6	124.6	124.6
Valuation ratios	0.6	0.8	0.9	1.0	1.0	0.9
P/BV EV/sales	0.6	0.8	0.9	0.3	0.2	
EV/Sales EV/EBITDA	1.3	11.9	11.1	0.3 5.5	3.2	0.2 1.9
EV/EBIT	2.8	-2.0	-5.8	-11.6	20.0	5.1
Source: Company data, NuWays	2.0	-2.0	-5.0	-11.0	20.0	J. I
outoo. Company data, Nurrayo						

Preview / Review - 06.03.2025



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
q.beyond AG	2

Historical target p	price and rating changes for	q.beyond AG			
Company	Date	Analyst	Rating	Target Price	Close
q.beyond AG	14.05.2024	Sennewald, Philipp	Buy	EUR 1.10	EUR 0.73

Preview / Review - 06.03.2025



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed com-

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 06/03/2025 08:02 AM

Date of publication dissemination: 06/03/2025 08:02 AM



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow

Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

Instagram



Twitter/>



LinkedIn

